What does ODAC mean in DRUGS
The Oncology Drugs Advisory Committee (ODAC) is a group of medical experts from the U.S. Food and Drug Administration who provide advice to the agency on decisions related to cancer drugs. The committee is an independent body that reviews new applications for oncology drugs, evaluates their safety and efficacy, and makes recommendations on their approval. The committee is composed of representatives from both industry and academia, who bring a variety of perspectives to the deliberations. By providing guidance on the drug approval process, ODAC helps ensure that medications reach those who need them most safely and effectively.
ODAC meaning in Drugs in Medical
ODAC mostly used in an acronym Drugs in Category Medical that means Oncology Drugs Advisory Committee
Shorthand: ODAC,
Full Form: Oncology Drugs Advisory Committee
For more information of "Oncology Drugs Advisory Committee", see the section below.
Essential Questions and Answers on Oncology Drugs Advisory Committee in "MEDICAL»DRUGS"
What is the Oncology Drugs Advisory Committee (ODAC)?
The ODAC is an independent committee of medical experts, which reviews oncology drugs for approval to market in the United States. It provides advice and recommendations to the U.S. Food and Drug Administration (FDA) about drug safety, effectiveness, and labeling. The ODAC works to ensure that only safe and effective drugs are approved for use by patients with cancer.
How does ODAC evaluate a new oncology drug?
The ODAC evaluates a new oncology drug based on its clinical trial results, data from pre-clinical studies, and other scientific evidence provided by the manufacturer. The committee members consider how the drug works compared to existing treatments as well as its potential risks and benefits before recommending approval or rejection of the new drug.
Who serves on ODAC?
The ODAC includes representatives from consumer organizations, patient advocacy groups, medical specialists in cancer treatments, researchers in cancer research, public health professionals, ethicists, pharmacists and other qualified individuals who have expertise in matters related to the development and evaluation of oncology drugs. Each member is appointed by the FDA Commissioner.
How often does ODAC meet?
The ODAC generally meets every three months for one day to review safety and efficacy data for new drugs as well as applications for expanded uses of existing drugs or biologics. Meetings are open to the public.
What happens after an ODAC meeting?
After an ODAC meeting has ended, a summary of each discussion will be released publicly within 30 days of the meeting date. Following this summary release, the FDA will make its final decision regarding approval or rejection of a new drug within 90 days after a meeting has concluded.
Can members of the public address their concerns during an Odac meeting?
Yes - members of the public can present their questions or concerns at designated times during each Odac meeting via webcast audio commentary or written comments submitted through an online portal managed by FDA's designated contact person prior to each meeting date.
Are live video broadcasts available for viewing Odac meetings?
Yes - webcasts are available for viewing each Odac session directly from FDA's webpage at http://www.fda.gov/AdvisoryCommittees/default.htm.The webcast is usually held about 30 minutes before actual start time.
Final Words:
In summary, ODAC plays an important role in ensuring that any new cancer drugs emerging onto the market are both safe and effective treatments for patients with cancer across the globe. As such, it serves as an invaluable insight into drug development research by bringing together industry representatives as well as top-tier academics who can assess each new application using objective principles based on strong scientific evidence before making recommendations to the FDA about these potentially life-saving treatments.
ODAC also stands for: |
|
| All stands for ODAC |